In summary, Engman and coworkers describe a rare case of syngeneic SCT in mantle cell lymphoma, which serves as an intriguing model to explore the benefit of high-dose strategies in this disease. Although these therapies have gained widespread use, their applicability is limited to a relatively small proportion of patients with MCL, and their effect on outcome is unclear. Continued prospective studies of these approaches are needed. The identification of new rational therapeutic targets in MCL has resulted in the recent introduction of many new agents including proteasome and mammalian target of rapamycin inhibitors.12,13 Early clinical trials of these agents have been promising and some are now being assessed as components of first-line therapy in this disease. If results in early phase studies are confirmed, the use of dose-intensive therapy may be more limited in patients with MCL in the future.
|Original language||English (US)|
|Number of pages||2|
|Journal||Clinical Advances in Hematology and Oncology|
|State||Published - Jun 9 2009|
ASJC Scopus subject areas